Nurix Therapeutics, Inc. NRIX
Set alert
At close · Oct 30
After hours · Oct 30, 4:21 PM ET
- YTD
- +41.28%
- 1 year
- +109.70%
- Open
- 26.90
- Prev close
- 27.12
- Mkt cap
- 2.93B
- Vol
- 2.31M
- Avg vol
- 1.70M
- EPS
- 2.43
- P/E
- 11.03
- Div yield
- 0.00%
More statistics
- Low
- 25.97
- High
- 26.92
- Forward P/E
- -21.01
- Beta
- 1.82
- Short ratio
- 10.30
- Inst. own
- 109.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 27, 2027
- 50-d avg
- 24.99
- 200-d avg
- 20.14
- 1y target
- 34.50
5D chart
Signals (106)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 10:55 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:40 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:35 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:40 AM | 1 day ago |
| RSI: Oversold | Oct 30, 9:40 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bullish | Oct 29, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 2 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 2 days ago |
| RSI: Oversold | Oct 29, 1:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:10 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:10 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 2 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:55 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 4 days ago |
| RSI: Overbought | Oct 27, 11:15 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:20 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 26, 3:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:25 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:10 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 5 days ago |
News
2 weeks ago benzinga.com
SpaceX To Rally Around 85%? Here Are 10 Top Analyst Forecasts For Friday
Wall Street analysts raised targets for MSTR, FOXA, NRIX, ZETA and TWLO, while cutting targets for CAMT and DVN.
-
2 weeks ago benzinga.com
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $36.
2 weeks ago seekingalpha.com
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
Nurix Therapeutics is maintained at "Strong Buy" due to pivotal progress with bexobrutideg, robust partnerships, and strong financials. The company initiated the phase 3 DAYBreak CLL-306 study,…
-
2 weeks ago benzinga.com
RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target from $36 to $35.
-
2 weeks ago benzinga.com
Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32
Oppenheimer analyst Kostas Biliouris maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $28 to $32.
-
2 weeks ago benzinga.com
Truist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33
Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $34 to $33.
-
2 weeks ago benzinga.com
Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36
Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.
2 weeks ago zacks.com
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
Nurix Therapeutics, Inc. (NRIX) came out with quarterly earnings of $4.73 per share, beating the Zacks Consensus Estimate of a loss of $0.56 per share. This compares to a loss of $1.03 per share a…
-
2 weeks ago benzinga.com
CORRECTION: Nurix Therapeutics Q3 EPS $4.73 Beats $3.98 Estimate, Sales $673.064M Beat $411.481M Estimate
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly earnings of $4.73 per share which beat the analyst consensus estimate of $3.98 by 18.84 percent. This is a 559.22 percent increase over losses of…
2 weeks ago globenewswire.com
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL
2 weeks ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
3 weeks ago benzinga.com
Stock Market: Will S&P 500 Open Up or Down Today?
Will S&P 500 open higher? Polymarket odds sit at 52% as Wall Street weighs 5.35% Treasury yields, potential Iran strikes, and Pepsi earnings.
-
3 weeks ago benzinga.com
Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration
First patient enrolled in cohort combining bexobrutideg with venetoclaxInitial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLLStrategy includes evaluation of…
3 weeks ago globenewswire.com
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of…
-
3 weeks ago benzinga.com
Nurix Gets $10M As Gilead Extends Drug Discovery Deal
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today…
3 weeks ago globenewswire.com
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE,…
1 month ago globenewswire.com
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of…
1 month ago defenseworld.net
842,089 Shares in Nurix Therapeutics, Inc. $NRIX Bought by Bank of America Corp DE
Bank of America Corp DE acquired a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ: NRIX) in the second quarter, according to the company in its most recent 13F filing with the Securities and…
1 month ago seekingalpha.com
Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
1 month ago seekingalpha.com
Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago zacks.com
Here's Why You Should Add NRIX Stock to Your Portfolio Now
Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.
1 month ago seekingalpha.com
Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
1 month ago zacks.com
Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why
Nurix Therapeutics (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 months ago globenewswire.com
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of…
2 months ago seekingalpha.com
Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case
Nurix secures a transformative Roche partnership, gaining $700M upfront, 50% U.S. profit share, and 60% Roche-funded global development for bexobrutideg. NRIX's financial runway is extended to ~3.5…
2 months ago globenewswire.com
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients…
2 months ago defenseworld.net
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade
Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday after Royal Bank Of Canada raised their price target on the stock from $33.00…
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.
-
2 months ago benzinga.com
Nurix Therapeutics Earns $10M Milestone Payment Following Initiation Of Sanofi's Phase 1 Clinical Study Of SAR448272/NX-3911
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today…
2 months ago globenewswire.com
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to…
2 months ago globenewswire.com
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitor Phase 3 trial…
-
3 months ago benzinga.com
Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38
Morgan Stanley analyst Terence Flynn maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $36 to $38.
3 months ago zacks.com
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum
RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.
-
3 months ago benzinga.com
UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31
UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $23 to $31.
-
3 months ago benzinga.com
Nurix Therapeutics To Carry 40% Of Clinical Development Costs Of Bexobrutideg, Roche To Carry 60%
Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential total payments of up…
-
3 months ago benzinga.com
Nurix Therapeutics To Receive $700M In Funding As Part Of Collaboration Agreement With Roche, Up To $2.3B After Milestone Payments
Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential total payments of up…
-
3 months ago benzinga.com
Nurix Therapeutics Finalizes Collaboration Agreement With Roche Following Expiration Of Regulatory Waiting Period
Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential total payments of up…
3 months ago globenewswire.com
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of…
-
3 months ago benzinga.com
Mizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $34
Mizuho analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $30 to $34.
-
3 months ago benzinga.com
Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $34
Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $32 to $34.
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $30 to $33.
-
3 months ago benzinga.com
Stifel Maintains Buy on Nurix Therapeutics, Raises Price Target to $40
Stifel analyst Stephen Willey maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $40.
-
3 months ago benzinga.com
BTIG Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target
BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $32 price target.
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $34
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $32 to $34.
-
3 months ago benzinga.com
Nurix Therapeutics Q2 EPS $(0.81) Misses $(0.74) Estimate, Sales $9.043M Miss $16.170M Estimate
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.74) by 9.46 percent. This is a 55.77 percent decrease over losses of…
4 months ago benzinga.com
Top 3 Health Care Stocks That May Keep You Up At Night In June
Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX, NRIX, GALT. Check BZ Edge Rankings for more.
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1…
-
4 months ago benzinga.com
Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33
Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $26 to $33.
-
4 months ago benzinga.com
Nurix to Present Updated CLL Drug Data at EHA 2026, Says Bexobrutideg Shows Durable Responses in CLL Trial
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today…
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $32 price target.